PVCT (Provectus Biopharmaceuticals) Ending Cash Position: $0.22 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Provectus Biopharmaceuticals Ending Cash Position?

Provectus Biopharmaceuticals PVCT -4.00% Ending Cash Position is $0.22 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Provectus Biopharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 was $0.22 Mil.

Provectus Biopharmaceuticals's quarterly Ending Cash Position increased from Sep. 2025 ($0.07 Mil) to Dec. 2025 ($0.25 Mil) but then declined from Dec. 2025 ($0.25 Mil) to Mar. 2026 ($0.22 Mil).

Provectus Biopharmaceuticals's annual Ending Cash Position declined from Dec. 2023 ($1.03 Mil) to Dec. 2024 ($0.49 Mil) and declined from Dec. 2024 ($0.49 Mil) to Dec. 2025 ($0.25 Mil).

Provectus Biopharmaceuticals Ending Cash Position Related Terms

Provectus Biopharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Provectus Biopharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Provectus Biopharmaceuticals Ending Cash Position Chart

Provectus Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.11 1.43 1.03 0.49 0.25

Provectus Biopharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.42 0.07 0.25 0.22

Provectus Biopharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Provectus Biopharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.489+-0.238
=0.25

Provectus Biopharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.252+-0.028
=0.22

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.22 Mil mean?
Provectus Biopharmaceuticals (PVCT) has a Ending Cash Position of $0.22 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Provectus Biopharmaceuticals and its competitors.
Is Provectus Biopharmaceuticals' Ending Cash Position too high?
Provectus Biopharmaceuticals' current Ending Cash Position is $0.22 Mil.
How does Provectus Biopharmaceuticals' Ending Cash Position compare to PSTV and ALGS?
Provectus Biopharmaceuticals' Ending Cash Position of $0.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Provectus Biopharmaceuticals and its competitors. Provectus Biopharmaceuticals's current Ending Cash Position is $0.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provectus Biopharmaceuticals stock overvalued right now?
Provectus Biopharmaceuticals (PVCT) has a current Ending Cash Position of $0.22 Mil. The current Ending Cash Position is $0.22 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Provectus Biopharmaceuticals (PVCT), the current Ending Cash Position is $0.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Provectus Biopharmaceuticals Business Description

Address 800 South Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.